M&A Deal Summary |
|
|---|---|
| Date | 2023-12-07 |
| Target | Vyera Pharmaceuticals - Daraprim & Vecamyl |
| Sector | Life Science |
| Buyer(s) | Tilde Sciences |
| Sellers(s) | Vyera Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2023 |
| Sector | Life Science |
Tilde Sciences is a biopharmaceutical company specializing in the development and commercialization of specialty pharmaceuticals tailored for rare diseases with significant unmet needs. Tilde Sciences was formed in 2023 and is based in Jersey City.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
Vyera Pharmaceuticals is a pharmaceutical company, developing therapies to treat patients suffering from serious and neglected diseases with unmet needs. Vyera Pharmaceuticals was formed in 2015 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
